Blog
RSS FeedPosted by Michael Wonder on 01 Feb 2022
Four million additional Australians eligible for their booster dose
31 January 2022 - Over four million additional Australians are now eligible for their COVID-19 booster dose from today, with the ...
Posted by Michael Wonder on 31 Jan 2022
Schedule of Pharmaceutical Benefits - 1 February 2022 update
1 February 2022 - The February 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Jan 2022
PBS listing to benefit Australians with rare type of non-Hodgkin lymphoma
31 January 2022 - From 1 February, thousands of Australians with a relapsed and/or refractory mantle cell lymphoma, a form of ...
Posted by Michael Wonder on 30 Jan 2022
How are child specific utility instruments used in decision making in Australia? A review of Pharmaceutical Benefits Advisory Committee public summary documents.
28 January 2022 - Measuring and valuing health-related quality of life in children can be challenging but is an important component ...
Posted by Michael Wonder on 28 Jan 2022
Recommendations made by the PBAC – December 2021 intracycle meeting
28 January 2022 - Recommendations made by the PBAC in December 2021 relating to the listing of medicines on the PBS ...
Posted by Michael Wonder on 28 Jan 2022
'I feel like I'm drowning': thousands with cystic fibrosis wait to hear if 'life-saving' drug will be listed on PBS
27 January 2022 - Matt Dickinson was struggling to breathe when his mother rushed him to an Adelaide hospital earlier ...
Posted by Michael Wonder on 28 Jan 2022
Australians deserve fast access to the latest medicines, vaccines and treatments
28 January 2022 - Medicines Australia recommends the Australian Government delivers a plan to shorten the time that patients wait ...
Posted by Michael Wonder on 27 Jan 2022
2022 April price disclosure cycle – indicative prices
27 January 2022 - Indicative 1 April 2022 prices resulting from the 2022 April Cycle of Price Disclosure have now been ...
Posted by Michael Wonder on 24 Jan 2022
Novavax COVID-19 vaccine to be available in coming weeks
24 January 2022 - Australians aged 18+ will now have access to a fourth COVID-19 vaccine, Nuvaxovid (Novavax) in coming weeks, ...
Posted by Michael Wonder on 24 Jan 2022
Australians with severe dermatitis to benefit from PBS listing
24 January 2022 - From 1 February 2022, Australians with severe atopic dermatitis will have access to a new treatment ...
Posted by Michael Wonder on 23 Jan 2022
Pharmacists struggle to meet demand for free COVID test kits amid stock shortage
23 January 2022 - Chemists across the country say they do not have enough rapid antigen tests to start handing ...
Posted by Michael Wonder on 23 Jan 2022
Thousands to benefit from decision to subsidise eczema treatment
23 January 2022 - Australians suffering from a severe form of eczema will save tens of thousands of dollars after a ...
Posted by Michael Wonder on 21 Jan 2022
National Medicines Policy Review – publication of submissions
21 January 2022 - On 30 August 2021, the National Medicines Policy Review Committee invited submissions to support the Review of ...
Posted by Michael Wonder on 14 Jan 2022
PBAC Public Summary Documents – September 2021 meeting (first time rejections and deferrals)
14 January 2022 - The Public Summary Documents (first time rejections and deferrals) from the September 2021 PBAC meeting are now ...
Posted by Michael Wonder on 06 Jan 2022
Updated agenda for the March 2022 PBAC meeting
5 January 2022 - The agenda for the March 2022 PBAC meeting has been updated. ...